Patent · US Active

Mutant MT-SP1 proteases with altered substrate specificity or activity

US8445245B2 · kind B2 · utility

12Cited by

40References

16Claims

0Family size

Assignee

Catalyst Biosciences, Inc. · US

Inventors

Sandra Waugh Ruggles · South San Francisco, US
Jack Nguyen · San Clemente, US

Key dates

Filing date	Mar 15, 2011
Grant date	May 21, 2013
Priority date	—
Expiry date	Mar 15, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N9/6424
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.